[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100239095":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":103,"centralContacts":107,"locations":114,"responsibleParty":133,"collaborators":135,"id":139,"slug":140,"hasResults":141,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":112,"eligibilityCriteria":145,"healthyVolunteers":141,"sex":146,"minAge":147,"maxAge":112,"enrollmentInfo":148,"targetDuration":112,"studyType":151,"phases":152,"briefSummary":154,"conditions":155,"keywords":112,"overallStatus":117,"whyStopped":112,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (18F-FDG PET\u002FCT, whole body PET\u002FMRI)","EXPERIMENTAL","Patients receive gadolinium IV and undergo whole body PET\u002FMRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET\u002FCT before start treatment for acute myeloid leukemia.",[13,14,15,16,17,18,19],"Procedure: Computed Tomography","Procedure: Diffusion Weighted Imaging","Radiation: Fludeoxyglucose F-18","Drug: Gadolinium","Procedure: Magnetic Resonance Imaging","Procedure: Positron Emission Tomography","Procedure: Three-Dimensional Spoiled Gradient MRI",[21,34,48,60,67,79,90],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Computed Tomography","Undergo 18F-FDG PET\u002FCT",[9],[27,28,29,30,31,32,33],"CAT","CAT Scan","Computerized Axial Tomography","computerized tomography","CT","CT SCAN","tomography",{"type":22,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Diffusion Weighted Imaging","Undergo whole body PET\u002FMRI",[9],[39,40,41,42,43,44,45,46,47],"Diffusion Weighted MRI","Diffusion-Weighted Magnetic Resonance Imaging","Diffusion-Weighted MR Imaging","Diffusion-Weighted MRI","DW-MRI","DWI","DWI MRI","DWI-MRI","MR Diffusion-Weighted Imaging",{"type":49,"name":50,"description":24,"armGroupLabels":51,"otherNames":52},"RADIATION","Fludeoxyglucose F-18",[9],[53,54,55,56,57,58,59],"18FDG","FDG","Fludeoxyglucose (18F)","fludeoxyglucose F 18","Fludeoxyglucose F18","Fluorine-18 2-Fluoro-2-deoxy-D-Glucose","Fluorodeoxyglucose F18",{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":65},"DRUG","Gadolinium","Given IV",[9],[66],"Gd",{"type":22,"name":68,"description":36,"armGroupLabels":69,"otherNames":70},"Magnetic Resonance Imaging",[9],[71,72,73,74,75,76,77,78],"Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR Imaging","MRI","MRI Scan","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging",{"type":22,"name":80,"description":81,"armGroupLabels":82,"otherNames":83},"Positron Emission Tomography","Undergo 18F-FDG PET\u002FCT and whole body PET\u002FMRI",[9],[84,85,86,87,88,89],"Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging",{"type":22,"name":91,"description":36,"armGroupLabels":92,"otherNames":93},"Three-Dimensional Spoiled Gradient MRI",[9],[94,95,96,97,98,99,100,101,102],"3-Dimensional Fast Spoiled Gradient","3D Fast Spoiled Gradient Recalled MRI","3D FSPGR","3DFSPGR","FSPGR","FSPGR MRI","SPGR","SPGR MRI","Three-Dimensional Spoiled Gradient-Echo MR",[104],{"name":105,"affiliation":5,"role":106},"Dawid Schellingerhout","PRINCIPAL_INVESTIGATOR",[108],{"name":109,"role":110,"phone":111,"phoneExt":112,"email":113},"Dawid Schellingerhout, MD","CONTACT","(713) 794-5673",null,"dawid.schellingerhout@mdanderson.org",[115],{"facility":116,"status":117,"city":118,"state":119,"zip":120,"country":121,"countryCode":122,"cosmosGeoPoint":123,"geoPoint":128,"contacts":129},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":124,"coordinates":125},"Point",[126,127],-95.36327,29.76328,{"lat":127,"lon":126},[130,132],{"name":109,"role":110,"phone":131,"phoneExt":112,"email":113},"713-794-5673",{"name":109,"role":106,"phone":112,"phoneExt":112,"email":112},{"type":134,"investigatorFullName":112,"investigatorTitle":112,"investigatorAffiliation":112,"oldNameTitle":112,"oldOrganization":112},"SPONSOR",[136],{"name":137,"class":138},"National Cancer Institute (NCI)","NIH","100239095","phase-1-petmri-18f-fdg-petct-and-whole-body-mri-in-finding-extramedullary-myeloid-leukemia-in-patients-with-newly-diagnosed-acute-myeloid-leukemia-100239095",false,"NCT02390635","PET\u002FMRI, 18F-FDG PET\u002FCT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia","PET\u002FMR, PET\u002FCT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\n* Patients with newly diagnosed AML\n* Non-English speaking subjects will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consenting non-English speaking subjects.\n\nExclusion Criteria:\n\n* Patients with contraindications to MR\n* Patients with a known allergy to MR contrast agents\n* Uncontrollable claustrophobia\n* Recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or Cytarabine more than 1 g per square meter.\n* Patients with secondary or relapsed AML or APL should be excluded.\n* Patients with known extramedullary leukemia\n* Positive pregnancy test in a female of childbearing potential\n* Younger than 18 years\n* Greater than 400 pounds in weight\n* Patients with uncontrolled diabetes\n* Cognitive impaired adults or prisoners will be excluded\n* Estimated glomerular filtration rate (eGFR \\\u003C30) will be excluded","ALL","18 Years",{"count":149,"type":150},77,"ESTIMATED","INTERVENTIONAL",[153],"PHASE1","This pilot phase I trial studies how well positron emission tomography (PET)\u002Fmagnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET\u002Fcomputed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET\u002FMRI, 18F-FDG PET\u002FCT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.",[156,157],"Acute Myeloid Leukemia","Acute Promyelocytic Leukemia With PML-RARA","2026-04-14",{"date":160,"type":161},"2026-04-17","ACTUAL",{"date":163,"type":161},"2020-07-15",{"date":165,"type":150},"2027-09-15",{"name":5,"class":6},1]